We will continue to work with NHS Boards and other partners to support a range of health improvement approaches for people with severe and enduring mental illness, and we will work with the Royal College of Psychiatrists in Scotland and other partners to develop a national standard for monitoring the physical health of people being treated with clozapine.
Clozapine is the "gold standard" antipsychotic for patients with treatment resistant schizophrenia, and is prescribed in line with good practice clinical guidelines (such as SIGN Guideline 131 on the Management of Schizophrenia). While outcomes of this treatment are good, unfortunately it is associated with a range of side-effects, some of which can have a profound effect on a patient’s on-going physical health.
A guideline development group was established to produce the standards with the overall aim of improving patient safety and the quality of care and treatment provided to people with schizophrenia.
The national standard for monitoring the physical health of people treated with clozapine was published on July 12, 2013:
The document defines minimum standards for physical health monitoring, in addition to manufacturer’s protocols, that should be applied to patients taking clozapine in Scotland.
Mental Health and Protection of Rights Division